The WSJ today reported that “New genetic research emerging from a major cancer meeting [annual meeting of the American Society of Clinical Oncology] could help doctors better identify the drugs most likely to work in their patients — but sharply reduce the market for certain blockbuster cancer drugs.”
Interesting that they are predicting more drug products for smaller markets. Apparently, “Both Amgen and Merck argue that patients who are successfully treated will stay on the drugs longer, potentially offsetting at least some of the impact of narrowing the target market.”
Personalized medicine and cancer drugs